{"id":7591,"date":"2025-12-07T08:00:53","date_gmt":"2025-12-07T07:00:53","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=congress-resource&#038;p=7591"},"modified":"2025-12-07T14:00:11","modified_gmt":"2025-12-07T13:00:11","slug":"phase-1-cadance-101-updated-results-of-btk-degrader-bgb-16673-in-rr-indolent-nhl","status":"publish","type":"congress-resource","link":"https:\/\/beonemedaffairs.com\/us\/congress-resource\/7591\/phase-1-cadance-101-updated-results-of-btk-degrader-bgb-16673-in-rr-indolent-nhl\/","title":{"rendered":"Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed\/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study"},"content":{"rendered":"","protected":false},"template":"","post-tag":[760,704,686,629,703,769,691,690,878,879,880],"class_list":["post-7591","congress-resource","type-congress-resource","status-publish","hentry","post-tag-american-society-of-hematology","post-tag-ash","post-tag-bgb-16673","post-tag-btk","post-tag-btk-degrader","post-tag-cadance-101","post-tag-cdac","post-tag-chimeric-degradation-activation-compound","post-tag-nhl","post-tag-non-hodgkin-lymphoma","post-tag-r-r-nhl","congress_resource_type-poster","content_type-reading","disease_state-non-hodgkin-lymphoma","molecule-bgb-16673"],"acf":{"congress_resource_url_override":"ash-2025","congress":6819,"category":245,"prioritization":0,"key_data_presentation":false,"key_data_presentation_only":false,"key_data_presentation_prioritization":0,"tags":[704,760,879,880,686,629,703,691,690,769],"visible_tags":[704,878,686],"content-type":246,"summary":"","text_app":"&nbsp;\r\n\r\nThis study assessed BGB-16673, an investigational drug that degrades the BTK protein, in 60 patients with follicular lymphoma (FL) or marginal zone lymphoma (MZL) who had received multiple prior treatments. BGB-16673 was generally well tolerated. The most common TEAEs in either group were fatigue and neutropenia. TEAEs led to 1 treatment discontinuation in the FL group and 5 in the MZL group, and 1 death due to intracranial hemorrhage occurred in the MZL group. In 48 response-evaluable patients, the overall response rate was 41% (7\/17) for FL, and 55% (17\/31) for MZL, including among patients previously treated with BTK inhibitors. Some patients achieved complete responses, and many remained on treatment. These results support further study of BGB-16673 for these lymphoma subtypes.\r\n\r\n<em>The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and\/or efficacy for such investigational products or uses may be made.<\/em>","text":"&nbsp;\r\n\r\nThis study assessed BGB-16673, an investigational drug that degrades the BTK protein, in 60 patients with follicular lymphoma (FL) or marginal zone lymphoma (MZL) who had received multiple prior treatments. BGB-16673 was generally well tolerated. The most common TEAEs in either group were fatigue and neutropenia. TEAEs led to 1 treatment discontinuation in the FL group and 5 in the MZL group, and 1 death due to intracranial hemorrhage occurred in the MZL group. In 48 response-evaluable patients, the overall response rate was 41% (7\/17) for FL, and 55% (17\/31) for MZL, including among patients previously treated with BTK inhibitors. Some patients achieved complete responses, and many remained on treatment. These results support further study of BGB-16673 for these lymphoma subtypes.\r\n\r\n<em>The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and\/or efficacy for such investigational products or uses may be made.<\/em>","table_heading":"","table":null,"faq_heading":"FREQUENTLY ASKED QUESTIONS","faq":null,"button_alt_link":"","no_post_image_preview":true,"download_file_reading":"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/12\/ASH2025_phase-1-cadance-101-updated-results-of-btk-degrader-bgb-16673-in-rr-indolent-nhl.pdf","display_file_reading":null,"download_file_slidekit":null,"display_file_slidekit":null,"3qsdn":"","webcast":"","vimeo_url":"","videolange":null,"fliphtml_link":"","use_pdf_instead_of_fliphtml":false,"congress_resource_abstract_link":"","congress_resource_cta_label":"See abstract","congress_resource_cta_link":"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/296938","authors":[7559],"field_page_schema_override":[{"field_page_schema_override_type":"PresentationDigitalDocument","field_page_schema_override_data":"{\r\n  \"@type\": \"PresentationDigitalDocument\",\r\n  \"name\": \"Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed\/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study \u2013 BeOne Medical Affairs | US\", \r\n  \"description\": \"Check out the ASH 2025 poster on updated results of BTK degrader BGB-16673 in R\/R indolent NHL patients from phase 1 CaDAnCe-101 study by Romain Gui\u00e8ze.\",  \r\n  \"image\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/11\/phase-1-cadance-101-updated-results-of-btk-degrader-bgb-16673-in-rr-indolent-nhl.jpeg\",\r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-1-cadance-101-updated-results-of-btk-degrader-bgb-16673-in-rr-indolent-nhl\/\",  \r\n  \"associatedMedia\": {\r\n    \"@type\": \"MediaObject\",\r\n    \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/296938\",\r\n    \"encodingFormat\": \"application\/pdf\"\r\n  },\r\n  \"datePublished\": \"2025-12-07\",  \r\n  \"keywords\": [\"bgb-16673 clinical trial\", \"btk degrader clinical trial\", \"BGB-16673 phase 1 data\", \"indolent NHL response results\", \"CaDAnCe-101 study of BTK degrader\"], \r\n  \"genre\": \"Poster\",   \r\n  \"author\": {\r\n    \"@type\": \"Person\",\r\n    \"name\": \"Romain Gui\u00e8ze, MD, PhD\"\r\n  },\r\n  \"publisher\": {\r\n    \"@type\": \"Organization\",\r\n    \"name\": \"BeOne Medicines\",\r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/\"\r\n  },\r\n  \"about\": {\r\n    \"@type\": \"MedicalStudy\",\r\n    \"name\": \"Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed\/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study\",  \r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-1-cadance-101-updated-results-of-btk-degrader-bgb-16673-in-rr-indolent-nhl\/\"\r\n  }\r\n}"},{"field_page_schema_override_type":"MedicalWebPage","field_page_schema_override_data":"{\r\n  \"@type\": \"MedicalWebPage\",   \r\n  \"name\": \"Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed\/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study \u2013 BeOne Medical Affairs | US\",   \r\n  \"description\": \"Check out the ASH 2025 poster on updated results of BTK degrader BGB-16673 in R\/R indolent NHL patients from phase 1 CaDAnCe-101 study by Romain Gui\u00e8ze.\",  \r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-1-cadance-101-updated-results-of-btk-degrader-bgb-16673-in-rr-indolent-nhl\/\", \r\n  \"inLanguage\": \"en-US\",\r\n  \"@logo\": {\r\n    \"@type\": \"ImageObject\",\r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/03\/BGI2404-BeOne-Primary-Logo-RGB-M04-V01-2.svg\"\r\n  }\r\n}"}]},"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource\/7591","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/congress-resource"}],"acf:post":[{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/authors\/7559"},{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress\/6819"}],"acf:term":[{"embeddable":true,"taxonomy":"content_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/content_type\/246"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/878"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/769"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/690"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/691"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/703"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/629"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/686"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/880"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/879"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/760"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/704"},{"embeddable":true,"taxonomy":"congress_resource_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress_resource_type\/245"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=7591"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=7591"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}